SOPHiA GENETICS (SOPH) Cash & Equivalents (2020 - 2025)

SOPHiA GENETICS's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $70.3 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 12.39% year-over-year to $70.3 million; the TTM figure through Dec 2025 stood at $70.3 million (down 12.39% YoY), while the FY2025 annual figure was $70.3 million, down 12.39% from the prior year.
• Cash & Equivalents came in at $70.3 million for Q4 2025 at SOPHiA GENETICS, down from $81.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $210.0 million in Q3 2021 to a low of $42.5 million in Q2 2021.
• A 5-year average of $122.5 million and a median of $114.3 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 45.17% in 2021 and jumped 321.07% in 2022, its largest moves.
• SOPHiA GENETICS's Cash & Equivalents stood at $193.0 million in 2021, then fell by 16.41% to $161.3 million in 2022, then slipped by 23.59% to $123.3 million in 2023, then slumped by 34.91% to $80.2 million in 2024, then dropped by 12.39% to $70.3 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $70.3 million, $81.6 million, and $94.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison